Compare EHang Holdings Ltd - ADR (EH) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs ResMed Inc. — how do they compare? EHang Holdings Ltd - ADR trades at $4.27 (market cap $309.45M), while ResMed Inc. trades at $228.81 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 103.1× EHang Holdings Ltd - ADR's market cap, and ResMed Inc. pays a 1.16% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and ResMed Inc. for 51 Days on average.
| EH | RMD | |
|---|---|---|
Market Cap | $309.45M | $31.89B |
Volume | 765,799 | 618,314 |
Sector | Industrials | Health |
52-Week High | $18.94 | $277.88 |
52-Week Low | $4.03 | $182.82 |
Typical Hold Time | 46 Days | 51 Days |
Enterprise Value | $261.14M | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.085, down 1.33% on the day, reflecting a bearish technical signal. The company shows a mixed fundamental picture with revenue of $418 million in 2025 but a net loss of $276 million, resulting in a net margin of -66.03%. Recent news includes ongoing legal investigations and expansion of its Global Fast Track Program to Vietnam. Cash flow trends are volatile, with a net cash outflow of $354 million in 2025 despite a strong cash position of $1.12 billion in 2024.
The outlook for EH is highly speculative, with significant execution and regulatory risks overshadowing its pioneering role in the eVTOL sector. While analyst consensus is divided (20% Buy, 40% Hold, 40% Sell), the stock's high volatility and negative profitability metrics suggest caution. Investment opportunity hinges on successful commercialization and regulatory approvals, but current financials and legal headwinds present substantial downside risks.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
